NIH inks $5m partnership with PathMaker Neurosystems for MyoRegulator spasticity device

PathMaker Neurosystems said today it signed a $5 million cooperative partnership deal with the National Institutes of Health to support continued development of its MyoRegulator neurostimulation system designed to treat spasticity secondary to stroke. The MyoRegulator device, based on PathMaker’s DoubleStim technology, is designed to provide simultaneous, non-invasive stimulation at spinal and peripheral locations, the Boston and Paris-based company said. The money comes as part of a four-year grant awarded through the CREATE Devices program which also provides a partnership with the NIH’s National Institute of Neurological Disorders and Stroke, PathMaker said. “We are truly honored and delighted to receive this support from NINDS to advance our breakthrough non-invasive neuromodulation technology that can benefit many patients in desperate need of treatment options. This collaborative partnership and funding will support product engineering, multi-center U.S. pivotal trials and regulatory submission for MyoRegulator,” prez &CEO Dr. Nader Yaghoubi said in a press release. “The CREATE Devices program encourages the pursuit of translational and clinical studies for innovative therapeutic devices to treat neurological disorders,” NINDS program director Nick Langhals said in a prepared statement. Last February, PathMaker Neurosystems said that it won a grant from BpiFrance to support its MyoRegulator neurostim device. The pos...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Neuromodulation/Neurostimulation PathMaker Neurosystems Inc. Source Type: news

Related Links:

(MedPage Today) -- This week's topics include occluding the atrial appendage and stroke, a pragmatic smoking trial, a relative rise in lung cancer among women, and the benefits of egg consumption
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
A person does not die directly from Alzheimer's disease; but instead, from complications caused by Alzheimer's disease.How do you know when a dementia patient is dying?Over time, and as Alzheimer's progresses, the body's immune system weakens, increasing susceptibility to infection and other causes of death related to the elderly.Typical complications from Alzheimer's and related dementia are:heart attacks, strokes, kidney failure, and lung infections due to aspiration of food. Multi-organ failure is often the cause of death in dementia patients.Learn More -Can you die from Alzheimer's disease?By Bob DeMarcoAlzheimer's Rea...
Source: Alzheimer's Reading Room, The - Category: Neurology Tags: alzheimer's alzheimer's care alzheimer's death Alzheimer's Dementia death alzheimer's dying alzheimer's dying dementia end of life caregiving family caergiving health searches related to alzheimer's Source Type: blogs
CONCLUSION: Therapist-assisted vision therapy increased peripheral visual awareness. Furthermore patients felt safer in the traffic and in outdoor activities. Reading speed significantly increased, and the ability to keep a moving object in focus improved. PMID: 29792389 [PubMed - as supplied by publisher]
Source: Neurological Research - Category: Neurology Tags: Neurol Res Source Type: research
DISCUSSION: Tramadol can ameliorate the histopathological structure of ischaemic tissue in both periods of I/R injury in rat. We suggest further research investigating various dosages with different administration methods of tramadol in stroke should be conducted by adopting different explorative techniques. PMID: 29792388 [PubMed - as supplied by publisher]
Source: Neurological Research - Category: Neurology Tags: Neurol Res Source Type: research
Publication date: Available online 25 May 2018 Source:Pharmacology & Therapeutics Author(s): Zhenhua Zhou, Jianfei Lu, Wen-Wu Liu, Anatol Manaenko, Xianhua Hou, Qiyong Mei, Jun-Long Huang, Jiping Tang, John H. Zhang, Honghong Yao, Qin Hu Stroke occurs when a cerebral blood vessel is blocked or ruptured, and it is the major cause of death and adult disability worldwide. Various pharmacological agents have been developed for the treatment of stroke either through interrupting the molecular pathways leading to neuronal death or enhancing neuronal survival and regeneration. Except for rtPA, few of these agents have succee...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Conclusions The MeCO exhibit potent cerebroprotective activity through its potent antioxidant and anti-inflammatory mechanisms, and hence may be useful in the management of ischemic stroke and associated complications. Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 25 May 2018 Source:Journal of Physiotherapy Author(s): Natasha Pocovi
Source: Journal of Physiotherapy - Category: Physiotherapy Source Type: research
Conclusions In a community-dwelling non-demented population, we describe patterns of association between hippocampal subregions with cognition and risk of dementia. Specifically, the subiculum was associated with both poorer cognition and higher risk of dementia.
Source: NeuroImage - Category: Neuroscience Source Type: research
Conclusion According to our meta-analysis TPC plus antiplatelets was superior in terms of stroke prevention when compared to Med-Tx. Furthermore, patients with moderate to severe shunts and those younger than 45 years of age were found to benefit most from TPC.
Source: American Heart Journal - Category: Cardiology Source Type: research
Conclusions ISCHEMIA will provide new scientific evidence regarding whether an invasive management strategy improves clinical outcomes when added to optimal medical therapy in patients with SIHD and moderate or severe ischemia.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Brain | Funding | Grants | National Institutes of Health (NIH) | Neurology | Partnerships | Stroke | Study